Professor Nancy Ross Appointed Vice-Principal, Research, at Queen’s University
After nearly 5 years as McGill’s Associate Vice-Principal, Research and Innovation (AVP-RI), Professor Nancy Ross is leaving McGill to join Queen’s University as Vice-Principal, Research. She will begin her appointment on August 1, 2021.
McGill to partner with CCRM in commercializing regenerative medicine
Ï㽶ÊÓƵ announced today it has concluded an agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to provide McGill-based startup companies with the benefit of CCRM’s market-leading business intelligence and experience.
$110M for Nine Innovative McGill Research Projects
Read the story in the McGill Reporter
Read the McGillÌýnews release
Marc Rousseau joins McGill as Director, Research Software
Research and Innovation and IT Services are pleased to welcome Marc Rousseau to the role of Director, Research Software / Directeur du Logiciel de Recherche. In this new role, Rousseau provides support and advice to the McGill research community on software, from grant applications to the implementation of research activities.
Diamond Therapeutics Signs Agreement with Ï㽶ÊÓƵ for Research on Low-Dose LSD
TORONTO,ÌýFeb. 4, 2021Ìý/CNW/ - Diamond Therapeutics Inc. ("Diamond"), a leading psychedelic drug development company focused on low-dose therapies for mental health, has entered into an agreement withÌýÏ㽶ÊÓƵÌýfor the exclusive use of Dr.ÌýGabriella Gobbi'sÌýgroundbreaking studies with lysergic acid diethylamide (LSD), its mechanism of action on the brain, and its potential for use at low doses in the treatment of mental health disorders.Ìý
Four McGill projects receive SSHRC Partnership Engage Grants
SSHRC invests over $80k in new McGill research projects through the Partnership Engage Grants competition, two of which are directly related to COVID-19 research.
Major European grant backs McGill research on rare condition
The European Joint Programme on Rare Diseases (EJP RD) has granted 1.6 million euros in support of an international research collaboration specific to the ultra-rare genetic disease, Schinzel-Giedion Syndrome (SGS).
McGill team wins grant to study ‘trained immunity’ with Japanese researchers
Joint research program between the Japan Agency for Medical Research and Development and the Canadian Institutes of Health Research focuses on advancing technologies in epigenomics, deepening McGill’s relationship with Japan’s RIKEN institute.
By Junji Nishihata
Reminder: Canada Research Continuity Emergency Fund (CRCEF)
This is a reminder to all principal investigators to complete their Canada Research Continuity Emergency Fund Stage 3 claims as soon as possible.
Kristina Öhrvall promoted to Assistant Vice-Principal, Research Development
Martha Crago, Vice-Principal, Research and Innovation, announced today that Kristina Öhrvall has been promoted to Assistant Vice-Principal, Research Development, for a five-year term.
Research and Innovation on a summer schedule, starting June 26
Please note that Research and Innovation (R+I), including all of its associated units, will soon change to a summer schedule as per McGill’s policy on Summer Fridays.
In practice, this means R+I will function with only minimal staff on Fridays throughout the summer, from June 26 until August 21. R+I will resume regular weekly office hours on Friday, August 28.
Updates on Research Support during the Pandemic
Sent on behalf of Martha Crago, Vice-Principal (Research and Innovation)
Ìý
Dear Colleagues,
I have been thinking of you often, as research is slowly ‎starting up again at McGill.
Call to McGill Researchers: Complete survey on COVID-19 Diagnostics R&D
The availability of reliable, rapid diagnostics is key to reopening our economies. Canada has an opportunity to take a leadership role in accelerating the development of these tests through a coordinated Canadian response. The goal is to support researchers to build networks and find collaborators/industry partners to advance their ideas to clinical trial and mass production. To that end, Dr.
Help fight COVID-19 by joining the CanCOVID initiative
McGill faculty with relevant expertise are encouraged to join the CanCOVID initiative, an expert community of Canadian COVID-19 researchers, clinical collaborators, and healthcare stakeholders.
McGill spinoff Laurent Pharmaceuticals to begin clinical trial on COVID-19 treatment
Company to run a Phase 2 clinical study with LAU-7b, a pro-resolving drug with potential antiviral properties against coronavirus